A Multicentre Retrospective Study of Anaplastic Thyroid Cancer in the Era of Targeted Therapy in a Public Health Care System: Canada's Experience

Abstract

Get full access to this article

View all access options for this article.

References

Maniakas

, Zafereo

, Cabanillas

. Anaplastic thyroid cancer: New horizons and challenges. Endocrinol Metab Clin North Am, 2022; 51(2):391–401; doi: 10.1016/j.ecl.2021.11.020

Subbiah

, Lassen

, Élez

, et al. Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol, 2020; 21(9):1234–1243; doi: 10.1016/S1470-2045(20)30321-1

Bible

, Kebebew

, Brierley

, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 2021; 31(3):337–386; doi: 10.1089/thy.2020.0944.Erratumin:Thyroid2021;31(10):1606-1607.

Maniakas

, Dadu

, Busaidy

, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000–2019. JAMA Oncol, 2020; 6(9):1397–1404; doi: 10.1001/jamaoncol.2020.3362

Prasongsook

, Kumar

, Chintakuntlawar

, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab, 2017; 102(12):4506–4514; doi: 10.1210/jc.2017-01180